

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
August 3, 2011
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 3, 2011.

2. Welcome

Debbie Tapley, R.Ph., called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Ed Behling, MD
Jony Bolinger, MD
Greg Browning, MD
Kelly Jones, PharmD

Jim Lindsay, MD
Sara Lindsey, MD
Thomas Phillips, R.Ph.
Tan Platt, MD

Debbie Tapley, R.Ph.
Ed Vess, R.Ph.

SC DHHS Staff:

James M Assey, R.Ph.
Deidra Singleton, JD
Valeria Williams

Magellan Medicaid Administration:

Bryan Amick, PharmD

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 4, 2011.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Speaker	Company	Drug/Class
Deborah Leverette, MD	General Comment	Antidepressants
Bill Lindsey	General Comment	Antidepressants
Judith Tolhurst, MD	Forest	Viibyrd
Joe Brown, PhD	General Comment	Insulin
Julie Ann Boggs, BSN	Lilly	Humalog/Humulin
Jamie Davis	General Comment	Insulin
Albert Humphrey, MD	General Comment	Insulin
Gary Riley	Abbott	Creon

C. Drug Classes for Review

Bryan Amick led the discussion for the following drug classes:

Antiemetic/Antivertigo Agents

Insulins

Minimally Sedating Antihistamines

Non-SSRI Antidepressants

Pancreatic Enzymes

Phosphodiesterase 5 Inhibitors for Pulmonary Arterial Hypertension

The chart below represents the recommendations from the P & T Committee:

ANTIDEPRESSANTS, OTHER	
Preferred BUPROPION BUPROPION SR BUPROPION XL MIRTAZAPINE NEFAZODONE PHENELZINE TRAZODONE VENLAFAXINE VENLAFAXINE ER CAPS	Non-Preferred APLENZIN EFFEXOR XR EMSAM OLEPTRO ER PRISTIQ VENLAFAXINE ER TABS VIIBRYD

ANTIEMETIC-ANTIVERTIGO AGENTS	
Preferred METOCLOPRAMIDE ONDANSETRON	Non-Preferred ANZEMET EMEND GRANISETRON MARINOL METOZOLV ODT SANCUSO ZUPLENZ

ANTIHISTAMINES, MINIMALLY SEDATING	
Preferred CETIRIZINE LORATADINE	Non-Preferred ALLEGRA CLARINEX CLARITIN FEXOFENADINE LEVOCETIRIZINE XYZAL
Combination products containing decongestants were removed from the class.	

HYPOGLYCEMICS, INSULIN AND RELA	
Preferred HUMALOG (Vials and Pens) HUMULIN (Vials and Pens) NOVOLIN (Vials and Pens) NOVOLOG (Vials and Pens)	Non-Preferred APIDRA (Vials and Pens)

PAH- PDE5 Inhibitors	
Preferred ADCIRCA REVATIO	Non-Preferred

PANCREATIC ENZYMES	
Preferred PANCRELIPASE CREON	Non-Preferred ZENPEP PANCREAZE

5. **Old Business**

None

6. **New Business**

None

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Antiemetic/Antivertigo Agents

Insulins

Minimally Sedating Antihistamines

Non-SSRI Antidepressants

Pancreatic Enzymes

Phosphodiesterase 5 Inhibitors for Pulmonary Arterial Hypertension

8. **Closing Comments**

The next meeting will be held on Wednesday, November 2, 2011, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 6:15 p.m.